• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    52 Weeks High And Low Article

    3/2/22 10:33:51 AM ET
    $ADAP
    $ADV
    $AGLE
    $AKA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Real Estate
    Get the next $ADAP alert in real time by email

     

     

    Wednesday's session saw 107 companies set new 52-week lows.

    Points of Interest From Today's 52-Week Lows:

    • Citigroup (NYSE:C) was the largest company by market cap to set a new 52-week low.
    • Mobiquity Technologies (NASDAQ:MOBQ) was the smallest company by market cap to set a new 52-week low.
    • SAB Biotherapeutics (NASDAQ:SABS)'s stock came under the most pressure, trading down 52.51% to reach a new 52-week low.
    • Neenah (NYSE:NP)'s shares had the biggest turnaround, impressively rebounding 0.0% after reaching a new 52-week low.

    Over the course of trading on Wednesday, the following stocks hit new 52-week lows:

    • Citigroup (NYSE:C) shares reached a new 52-week low of $55.93 on Wednesday morning, moving down 4.46%.
    • Dr Reddy's Laboratories (NYSE:RDY) shares set a new 52-week low of $50.15. The stock traded down 2.58%.
    • HashiCorp (NASDAQ:HCP) shares moved down 6.63% on Wednesday to hit a new 52-week low of $44.50, drifting down 6.63%.
    • GoodRx Holdings (NASDAQ:GDRX) shares made a new 52-week low of $15.82 on Wednesday. The stock was down 4.66% for the day.
    • Weibo (NASDAQ:WB) stock dropped to a yearly low on Wednesday of $26.62. Shares traded down 0.61%.
    • Ardagh Metal Packaging (NYSE:AMBP) stock broke to a new 52-week low of $7.72 on Wednesday. Shares of the company traded up 0.58%.
    • Certara (NASDAQ:CERT) stock set a new 52-week low of $20.51 on Wednesday, moving down 10.1%.
    • Duolingo (NASDAQ:DUOL) shares fell to $77.59 on Wednesday, setting a new 52-week low with a shift of down 5.2%.
    • Kyndryl Hldgs (NYSE:KD) stock dropped to a yearly low on Wednesday of $12.88. Shares traded down 3.33%.
    • Bumble (NASDAQ:BMBL) stock hit a yearly low of $22.08. The stock was down 3.34% for the day.
    • Diversey Holdings (NASDAQ:DSEY) shares fell to $8.83 on Wednesday, setting a new 52-week low with a shift of down 4.19%.
    • United Breweries Co (NYSE:CCU) shares set a new yearly low of $14.79 this morning. The stock was down 0.6% on the session.
    • BRF (NYSE:BRFS) shares made a new 52-week low of $3.07 on Wednesday. The stock was down 1.67% for the day.
    • PTC Therapeutics (NASDAQ:PTCT) stock hit a yearly low of $33.82. The stock was down 0.47% for the day.
    • Advantage Solutions (NASDAQ:ADV) shares moved down 10.38% on Wednesday to hit a new 52-week low of $6.09, drifting down 10.38%.
    • Enel Chile (NYSE:ENIC) shares reached a new 52-week low of $1.54 on Wednesday morning, moving down 3.7%.
    • Manchester United (NYSE:MANU) shares moved up 0.31% on Wednesday to hit a new 52-week low of $12.74, drifting up 0.31%.
    • Qurate Retail (NASDAQ:QRTEB) stock hit a yearly low of $5.44. The stock was down 9.33% for the day.
    • Noah Holdings (NYSE:NOAH) shares moved down 4.4% on Wednesday to hit a new 52-week low of $25.62, drifting down 4.4%.
    • Dave (NASDAQ:DAVE) stock hit a yearly low of $4.09. The stock was down 3.95% for the day.
    • Allbirds (NASDAQ:BIRD) shares fell to $7.01 on Wednesday, setting a new 52-week low with a shift of down 7.88%.
    • Shenandoah (NASDAQ:SHEN) shares set a new 52-week low of $19.74. The stock traded up 1.01%.
    • American Well (NYSE:AMWL) shares were down 5.5% for the day, having made a 52-week low of $3.67.
    • Butterfly Network (NYSE:BFLY) shares set a new yearly low of $4.56 this morning. The stock was down 5.32% on the session.
    • ATRenew (NYSE:RERE) shares set a new yearly low of $3.94 this morning. The stock was down 2.64% on the session.
    • Atara Biotherapeutics (NASDAQ:ATRA) shares were down 3.04% for the day, having made a 52-week low of $9.63.
    • Science 37 Hldgs (NASDAQ:SNCE) shares were down 2.17% for the day, having made a 52-week low of $7.20.
    • Hydrofarm Holdings Group (NASDAQ:HYFM) shares set a new yearly low of $16.56 this morning. The stock was down 11.02% on the session.
    • a.k.a. Brands Holding (NYSE:AKA) shares set a new 52-week low of $5.07. The stock traded down 24.5%.
    • ZimVie (NASDAQ:ZIMV) stock hit a new 52-week low of $24.50. The stock was up 0.04% on the session.
    • Diebold Nixdorf (NYSE:DBD) stock set a new 52-week low of $7.53 on Wednesday, moving up 0.38%.
    • Neenah (NYSE:NP) shares fell to $35.48 on Wednesday, setting a new 52-week low with a shift of 0.0% (flat).
    • Groupon (NASDAQ:GRPN) shares set a new yearly low of $18.97 this morning. The stock was down 3.64% on the session.
    • Loyalty Ventures (NASDAQ:LYLT) shares set a new yearly low of $21.74 this morning. The stock was down 1.04% on the session.
    • Vital Farms (NASDAQ:VITL) stock broke to a new 52-week low of $13.03 on Wednesday. Shares of the company traded down 2.76%.
    • IDEAYA Biosciences (NASDAQ:IDYA) stock broke to a new 52-week low of $12.62 on Wednesday. Shares of the company traded up 0.08%.
    • Vroom (NASDAQ:VRM) shares hit a yearly low of $3.03. The stock was down 2.62% on the session.
    • Kodiak Sciences (NASDAQ:KOD) shares fell to $8.19 on Wednesday, setting a new 52-week low with a shift of down 6.22%.
    • Purple Innovation (NASDAQ:PRPL) shares set a new 52-week low of $5.05. The stock traded up 10.73%.
    • Adaptimmune Therapeutics (NASDAQ:ADAP) shares made a new 52-week low of $2.28 on Wednesday. The stock was down 2.49% for the day.
    • ATI Physical Therapy (NYSE:ATIP) stock hit a yearly low of $1.73. The stock was down 5.29% for the day.
    • Morgan Stanley Emerging (NYSE:EDD) shares reached a new 52-week low of $5.07 on Wednesday morning, moving down 0.39%.
    • Semler Scientific (NASDAQ:SMLR) stock hit $49.72 on Wednesday morning, setting a new 52-week low for a change of down 5.55%.
    • Templeton Emerging Market (NYSE:TEI) stock hit $6.71 on Wednesday morning, setting a new 52-week low for a change of up 0.11%.
    • 1stdibs.com (NASDAQ:DIBS) shares set a new yearly low of $6.49 this morning. The stock was down 23.18% on the session.
    • Lexicon Pharmaceuticals (NASDAQ:LXRX) stock dropped to a yearly low on Wednesday of $2.00. Shares traded down 4.5%.
    • Marinus Pharmaceuticals (NASDAQ:MRNS) shares were down 1.56% for the day, having made a 52-week low of $7.51.
    • Oyster Point Pharma (NASDAQ:OYST) shares fell to $8.57 on Wednesday, setting a new 52-week low with a shift of down 4.71%.
    • Romeo Power (NYSE:RMO) stock set a new 52-week low of $1.50 on Wednesday, moving down 10.0%.
    • Hemisphere Media (NASDAQ:HMTV) stock set a new 52-week low of $4.96 on Wednesday, moving up 1.4%.
    • Zevia (NYSE:ZVIA) stock dropped to a yearly low on Wednesday of $5.68. Shares traded down 4.23%.
    • Annexon (NASDAQ:ANNX) shares reached a new 52-week low of $4.56 on Wednesday morning, moving down 2.75%.
    • Cue Biopharma (NASDAQ:CUE) stock set a new 52-week low of $5.28 on Wednesday, moving down 5.03%.
    • Cyteir Therapeutics (NASDAQ:CYT) stock set a new 52-week low of $4.58 on Wednesday, moving down 5.07%.
    • Werewolf Therapeutics (NASDAQ:HOWL) shares reached a new 52-week low of $5.70 on Wednesday morning, moving down 2.57%.
    • Pyxis Oncology (NASDAQ:PYXS) shares set a new yearly low of $4.75 this morning. The stock was down 5.83% on the session.
    • Fortress Biotech (NASDAQ:FBIO) stock drifted down 7.23% on Wednesday morning to hit a new 52-week low of $1.52.
    • GoHealth (NASDAQ:GOCO) shares reached a new 52-week low of $1.21 on Wednesday morning, moving down 34.67%.
    • Synchronoss Technologies (NASDAQ:SNCR) shares made a new 52-week low of $1.51 on Wednesday. The stock was down 0.33% for the day.
    • Jasper Therapeutics (NASDAQ:JSPR) shares fell to $3.31 on Wednesday, setting a new 52-week low with a shift of down 2.29%.
    • Aeglea BioTherapeutics (NASDAQ:AGLE) shares moved down 1.87% on Wednesday to hit a new 52-week low of $2.52, drifting down 1.87%.
    • Tuesday Morning (NASDAQ:TUEM) shares moved down 0.72% on Wednesday to hit a new 52-week low of $1.36, drifting down 0.72%.
    • Sonendo (NYSE:SONX) shares moved down 6.08% on Wednesday to hit a new 52-week low of $4.32, drifting down 6.08%.
    • Exagen (NASDAQ:XGN) shares moved down 1.12% on Wednesday to hit a new 52-week low of $7.04, drifting down 1.12%.
    • Esports Technologies (NASDAQ:EBET) stock dropped to a yearly low on Wednesday of $7.16. Shares traded up 4.75%.
    • Black Diamond Therapeutic (NASDAQ:BDTX) stock set a new 52-week low of $2.82 on Wednesday, moving down 4.61%.
    • Sensei Biotherapeutics (NASDAQ:SNSE) shares moved down 3.97% on Wednesday to hit a new 52-week low of $3.30, drifting down 3.97%.
    • Frequency Therapeutics (NASDAQ:FREQ) shares set a new yearly low of $2.71 this morning. The stock was up 0.73% on the session.
    • SAB Biotherapeutics (NASDAQ:SABS) shares moved down 52.51% on Wednesday to hit a new 52-week low of $2.15, drifting down 52.51%.
    • Zedge (AMEX:ZDGE) stock hit $5.76 on Wednesday morning, setting a new 52-week low for a change of down 8.23%.
    • Zynerba Pharmaceuticals (NASDAQ:ZYNE) stock hit a yearly low of $2.05. The stock was down 4.63% for the day.
    • First Trust/aberdeen Glb (NYSE:FAM) stock hit a new 52-week low of $7.80. The stock was down 0.63% on the session.
    • Elevation Oncology (NASDAQ:ELEV) stock broke to a new 52-week low of $3.20 on Wednesday. Shares of the company traded down 1.21%.
    • Miromatrix Medical (NASDAQ:MIRO) stock hit a yearly low of $3.50. The stock was down 6.17% for the day.
    • Better Therapeutics (NASDAQ:BTTX) stock achieved a new 52-week low on Wednesday morning, hitting $2.61 and moving down 4.63%.
    • CENTRAL & EASTERN EUROPE (NYSE:CEE) stock set a new 52-week low of $9.30 on Wednesday, moving down 14.19%.
    • Angion Biomedica (NASDAQ:ANGN) shares set a new 52-week low of $1.80. The stock traded down 4.0%.
    • First Trust/aberdeen (NYSE:FEO) shares made a new 52-week low of $11.36 on Wednesday. The stock was down 1.96% for the day.
    • Lixiang Education Holding (NASDAQ:LXEH) stock dropped to a yearly low on Wednesday of $4.05. Shares traded down 10.2%.
    • Applied Therapeutics (NASDAQ:APLT) stock broke to a new 52-week low of $1.81 on Wednesday. Shares of the company traded down 2.13%.
    • Femasys (NASDAQ:FEMY) shares moved down 3.01% on Wednesday to hit a new 52-week low of $2.52, drifting down 3.01%.
    • Cohen & Co (AMEX:COHN) shares set a new yearly low of $14.06 this morning. The stock was down 3.15% on the session.
    • Elite Education Gr Intl (NASDAQ:EEIQ) stock broke to a new 52-week low of $2.04 on Wednesday. Shares of the company traded down 8.26%.
    • Immix Biopharma (NASDAQ:IMMX) shares reached a new 52-week low of $2.72 on Wednesday morning, moving up 0.36%.
    • Eco Wave Power Global (NASDAQ:WAVE) stock achieved a new 52-week low on Wednesday morning, hitting $3.77 and moving down 12.67%.
    • Revelation Biosciences (NASDAQ:REVB) stock set a new 52-week low of $1.23 on Wednesday, moving down 7.52%.
    • InMed Pharmaceuticals (NASDAQ:INM) shares reached a new 52-week low of $0.85 on Wednesday morning, moving down 2.05%.
    • Nuwellis (NASDAQ:NUWE) shares hit a yearly low of $0.85. The stock was down 3.19% on the session.
    • Mobiquity Technologies (NASDAQ:MOBQ) shares moved down 2.44% on Wednesday to hit a new 52-week low of $1.20, drifting down 2.44%.

     

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ADAP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAP
    $ADV
    $AGLE
    $AKA

    CompanyDatePrice TargetRatingAnalyst
    Allbirds Inc.
    $BIRD
    2/4/2026Buy → Hold
    Maxim Group
    PTC Therapeutics Inc.
    $PTCT
    1/28/2026$119.00Overweight
    Barclays
    Kyndryl Holdings Inc.
    $KD
    1/27/2026$40.00Sector Outperform
    Scotiabank
    GoodRx Holdings Inc.
    $GDRX
    1/22/2026$2.75Buy → Hold
    Jefferies
    Zevia PBC
    $ZVIA
    1/15/2026$4.00Buy
    Craig Hallum
    Jasper Therapeutics Inc.
    $JSPR
    1/13/2026$17.00Buy
    Rodman & Renshaw
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    IDEAYA Biosciences Inc.
    $IDYA
    1/7/2026$50.00Buy
    UBS
    More analyst ratings

    $ADAP
    $ADV
    $AGLE
    $AKA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Allbirds downgraded by Maxim Group

    Maxim Group downgraded Allbirds from Buy to Hold

    2/4/26 8:06:33 AM ET
    $BIRD
    Apparel
    Consumer Discretionary

    Barclays resumed coverage on PTC Therapeutics with a new price target

    Barclays resumed coverage of PTC Therapeutics with a rating of Overweight and set a new price target of $119.00

    1/28/26 7:18:18 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank resumed coverage on Kyndryl with a new price target

    Scotiabank resumed coverage of Kyndryl with a rating of Sector Outperform and set a new price target of $40.00

    1/27/26 8:47:13 AM ET
    $KD
    EDP Services
    Technology

    $ADAP
    $ADV
    $AGLE
    $AKA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Invus Global Management, Llc was granted 22,400,000 shares, bought $2,000,001 worth of shares (1,538,462 units at $1.30) and was granted 367,145 units of Series B Convertible Preferred Stock (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/4/26 4:25:05 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $20,657 worth of shares (4,115 units at $5.02), increasing direct ownership by 8% to 54,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    1/2/26 4:30:06 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sarraf Pasha bought $99,747 worth of shares (323,857 units at $0.31) (SEC Form 4)

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    1/2/26 4:00:03 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ADV
    $AGLE
    $AKA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

    THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ("Lexicon") today announced the closing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001, and concurrent private placement of 22,400,000 shares of common stock and 367,145 shares of series b convertible preferred stock (the "Series B Convertible Preferred Stock"). The shares of common stock offered pursuant to the public offering were sold at a public offering price of $1.30 per share and the shares of preferred stock were sold at a price of $65 per share. The offerings closed on February 2, 2026. In addition to the shares s

    2/6/26 5:17:00 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GoodRx Powers Pricing for Leading Brand Medications on TrumpRx

    Brief Summary: GoodRx is a core integration partner for TrumpRx, powering the pricing for leading brand medications At launch, GoodRx is the integrated pricing source on TrumpRx for Pfizer, including over 30 of Pfizer's essential brand medications spanning women's health, arthritis, and more By unifying pricing, pharmacy enablement, and a trusted consumer experience, GoodRx enables pharma manufacturers to rapidly deploy and scale emerging pricing models with minimal operational lift GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced that it is a key integration partner for pharmaceutical companies offering discounted cash prices on T

    2/5/26 7:44:00 PM ET
    $GDRX
    EDP Services
    Technology

    Shenandoah Telecommunications Company to Hold its Fourth Quarter and Full Year 2025 Earnings Call at 8:30 a.m. on Thursday, February 26, 2026

    EDINBURG, Va., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (Shentel) (NASDAQ:SHEN) will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026, and will host a conference call and simultaneous webcast on the same day at 8:30 a.m. Eastern Time to discuss Shentel's financial results and business highlights. Date: February 26, 2026Time: 8:30 AM ET Listen via Internet: https://investor.shentel.com/ For Analysts, please register to dial-in at this link. A replay of the call will be available for a limited time on the Investor Relations page of the Company's website. About Shenandoah Telecommunicatio

    2/5/26 4:15:00 PM ET
    $SHEN
    Telecommunications Equipment
    Telecommunications

    $ADAP
    $ADV
    $AGLE
    $AKA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

    Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

    5/30/23 10:02:49 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for TYRVAYA issued to OYSTER POINT PHARMA INC

    Submission status for OYSTER POINT PHARMA INC's drug TYRVAYA (ORIG-1) with active ingredient VARENICLINE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 213978, Application Classification: Type 3 - New Dosage Form

    10/19/21 7:27:01 PM ET
    $OYST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ADV
    $AGLE
    $AKA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Peacock David A covered exercise/tax liability with 57,167 shares, decreasing direct ownership by 2% to 3,501,366 units (SEC Form 4)

    4 - Advantage Solutions Inc. (0001776661) (Issuer)

    2/6/26 4:30:05 PM ET
    $ADV
    Real Estate

    VP Chief HRO Tormey Heather K was granted 5,606 shares and covered exercise/tax liability with 1,983 shares, increasing direct ownership by 23% to 19,322 units (SEC Form 4)

    4 - SHENANDOAH TELECOMMUNICATIONS CO/VA/ (0000354963) (Issuer)

    2/5/26 9:32:35 PM ET
    $SHEN
    Telecommunications Equipment
    Telecommunications

    SVP Sales & Marketing Leslie Dara was granted 7,259 shares and covered exercise/tax liability with 2,528 shares, increasing direct ownership by 83% to 10,404 units (SEC Form 4)

    4 - SHENANDOAH TELECOMMUNICATIONS CO/VA/ (0000354963) (Issuer)

    2/5/26 9:27:01 PM ET
    $SHEN
    Telecommunications Equipment
    Telecommunications

    $ADAP
    $ADV
    $AGLE
    $AKA
    SEC Filings

    View All

    SEC Form FWP filed by Lexicon Pharmaceuticals Inc.

    FWP - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    2/6/26 5:17:30 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Citigroup Inc.

    FWP - CITIGROUP INC (0000831001) (Subject)

    2/6/26 4:44:35 PM ET
    $C
    Major Banks
    Finance

    SEC Form 8-K filed by Werewolf Therapeutics Inc.

    8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)

    2/6/26 4:41:00 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ADV
    $AGLE
    $AKA
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ADV
    $AGLE
    $AKA
    Leadership Updates

    Live Leadership Updates

    View All

    Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

    BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology's Board of Directors since the Company's IPO and a highly experienced biotechnology executive with a proven track record in advancing cancer therapeutics, has been appointed Interim Chief Executive Officer, effective immediately. Lara S. Sullivan, M.D., has stepped down from her roles as President, Chief Executive Officer and Chief Medical Officer. With

    2/3/26 6:45:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis Appoints Carisa Schultz as Chief Financial Officer

    MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including A

    1/30/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Announces Changes to Board of Directors

    MINNEAPOLIS, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced the appointment of Katharyn Field and Mika Grasso to its board of directors, effective January 21, 2026. Ms. Field is the Chief Executive Officer of ISpecimen Inc., where she oversees performance improvement and the redevelopment of the proprietary software platform. Prior to serving as Chief Executive Officer she served as President, Chairman, and as an independent director. She has served as a director of LogProstyle since September 2024, as an Executive Director of Akanda Corporation since Ju

    1/23/26 4:40:27 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADAP
    $ADV
    $AGLE
    $AKA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Citigroup Inc.

    SC 13D - CITIGROUP INC (0000831001) ()

    1/5/94 12:00:00 AM ET
    $C
    Major Banks
    Finance

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/17/24 5:51:04 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by Groupon Inc.

    SC 13G - Groupon, Inc. (0001490281) (Subject)

    12/13/24 10:39:00 AM ET
    $GRPN
    Advertising
    Consumer Discretionary

    $ADAP
    $ADV
    $AGLE
    $AKA
    Financials

    Live finance-specific insights

    View All

    Shenandoah Telecommunications Company to Hold its Fourth Quarter and Full Year 2025 Earnings Call at 8:30 a.m. on Thursday, February 26, 2026

    EDINBURG, Va., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (Shentel) (NASDAQ:SHEN) will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026, and will host a conference call and simultaneous webcast on the same day at 8:30 a.m. Eastern Time to discuss Shentel's financial results and business highlights. Date: February 26, 2026Time: 8:30 AM ET Listen via Internet: https://investor.shentel.com/ For Analysts, please register to dial-in at this link. A replay of the call will be available for a limited time on the Investor Relations page of the Company's website. About Shenandoah Telecommunicatio

    2/5/26 4:15:00 PM ET
    $SHEN
    Telecommunications Equipment
    Telecommunications

    Dave Reports Preliminary Fourth Quarter and Full Year 2025 Results

    2025 Revenue and Adjusted EBITDA Results are Expected to Exceed the Top-End of Guidance 4Q25 28 DPD Rate Expected to be Within the Range of 1.95%-2.00%, Outperforming Guidance of Below 2.10% Full Earnings Results and 2026 Financial Outlook to Be Discussed on March 2, 2026 at 5:00pm ET LOS ANGELES, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced certain preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company expects to release full, audited financial results and file its annual report on Form 10-K for the year ended December 31, 2025 on Mar

    2/5/26 4:15:00 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    Amwell® to report fourth quarter and full year 2025 operating results

    BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report fourth quarter and full year 2025 operating results after stock market trading hours on Thursday, Feb. 12. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at

    2/5/26 4:05:00 PM ET
    $AMWL
    Real Estate